210 related articles for article (PubMed ID: 31118962)
1. Mistletoe and Immunomodulation: Insights and Implications for Anticancer Therapies.
Oei SL; Thronicke A; Schad F
Evid Based Complement Alternat Med; 2019; 2019():5893017. PubMed ID: 31118962
[TBL] [Abstract][Full Text] [Related]
2. Clinical safety of combined therapy of immune checkpoint inhibitors and Viscum album L. therapy in patients with advanced or metastatic cancer.
Thronicke A; Steele ML; Grah C; Matthes B; Schad F
BMC Complement Altern Med; 2017 Dec; 17(1):534. PubMed ID: 29237435
[TBL] [Abstract][Full Text] [Related]
3. Viscum album L. Therapy in Oncology: An Update on Current Evidence.
Thronicke A; Schad F; Debus M; Grabowski J; Soldner G
Complement Med Res; 2022; 29(4):362-368. PubMed ID: 35325897
[TBL] [Abstract][Full Text] [Related]
4. Immune-related and adverse drug reactions to low versus high initial doses of Viscum album L. in cancer patients.
Schad F; Thronicke A; Merkle A; Matthes H; Steele ML
Phytomedicine; 2017 Dec; 36():54-58. PubMed ID: 29157828
[TBL] [Abstract][Full Text] [Related]
5. Safety of Combined Targeted and Helixor
Schad F; Thronicke A
Int J Environ Res Public Health; 2023 Jan; 20(3):. PubMed ID: 36767928
[TBL] [Abstract][Full Text] [Related]
6. [Mistletoe in the treatment of cancer patients].
Rostock M
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2020 May; 63(5):535-540. PubMed ID: 32211937
[TBL] [Abstract][Full Text] [Related]
7. Use and safety of intratumoral application of European mistletoe (Viscum album L) preparations in Oncology.
Steele ML; Axtner J; Happe A; Kröz M; Matthes H; Schad F
Integr Cancer Ther; 2015 Mar; 14(2):140-8. PubMed ID: 25552476
[TBL] [Abstract][Full Text] [Related]
8. Clinical Safety of Combined Targeted and
Thronicke A; Oei SL; Merkle A; Matthes H; Schad F
Medicines (Basel); 2018 Sep; 5(3):. PubMed ID: 30200590
[No Abstract] [Full Text] [Related]
9. Inability of galactoside-specific mistletoe lectin to inhibit N-methyl-N-nitrosourea-induced tumor development in the urinary bladder of rats and to mediate a local cellular immune response after long-term administration.
Kunze E; Schulz H; Gabius HJ
J Cancer Res Clin Oncol; 1998; 124(2):73-87. PubMed ID: 9654190
[TBL] [Abstract][Full Text] [Related]
10. Proteomic fingerprinting of mistletoe (Viscum album L.) via combinatorial peptide ligand libraries and mass spectrometry analysis.
Vergara-Barberán M; Lerma-García MJ; Nicoletti M; Simó-Alfonso EF; Herrero-Martínez JM; Fasoli E; Righetti PG
J Proteomics; 2017 Jul; 164():52-58. PubMed ID: 28571969
[TBL] [Abstract][Full Text] [Related]
11. [Mistletoe (Viscum album) preparations: an optional drug for cancer patients?].
Bar-Sela G; Gershony A; Haim N
Harefuah; 2006 Jan; 145(1):42-6, 77. PubMed ID: 16450726
[TBL] [Abstract][Full Text] [Related]
12. Safety of Combined Treatment With Monoclonal Antibodies and Viscum album L Preparations.
Schad F; Axtner J; Kröz M; Matthes H; Steele ML
Integr Cancer Ther; 2018 Mar; 17(1):41-51. PubMed ID: 29444603
[TBL] [Abstract][Full Text] [Related]
13. Induction of apoptosis of endothelial cells by Viscum album: a role for anti-tumoral properties of mistletoe lectins.
Duong Van Huyen JP; Bayry J; Delignat S; Gaston AT; Michel O; Bruneval P; Kazatchkine MD; Nicoletti A; Kaveri SV
Mol Med; 2002 Oct; 8(10):600-6. PubMed ID: 12477970
[TBL] [Abstract][Full Text] [Related]
14. Health services research of integrative oncology in palliative care of patients with advanced pancreatic cancer.
Axtner J; Steele M; Kröz M; Spahn G; Matthes H; Schad F
BMC Cancer; 2016 Aug; 16():579. PubMed ID: 27485618
[TBL] [Abstract][Full Text] [Related]
15. Molecular mechanisms underlying the immunomodulatory effects of mistletoe (Viscum album L.) extracts Iscador.
Elluru S; Duong Van Huyen JP; Delignat S; Prost F; Bayry J; Kazatchkine MD; Kaveri SV
Arzneimittelforschung; 2006 Jun; 56(6A):461-6. PubMed ID: 16927527
[TBL] [Abstract][Full Text] [Related]
16.
Bonamin LV; de Carvalho AC; Waisse S
Exp Ther Med; 2017 Jun; 13(6):2723-2740. PubMed ID: 28596809
[TBL] [Abstract][Full Text] [Related]
17. Use and Safety of Viscum album L Applications in Cancer Patients With Preexisting Autoimmune Diseases: Findings From the Network Oncology Study.
Oei SL; Thronicke A; Kröz M; Matthes H; Schad F
Integr Cancer Ther; 2019; 18():1534735419832367. PubMed ID: 30808274
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant Cancer Biotherapy by Viscum Album Extract Isorel: Overview of Evidence Based Medicine Findings.
Sunjic SB; Gasparovic AC; Vukovic T; Weiss T; Weiss ES; Soldo I; Djakovic N; Zarkovic T; Zarkovic N
Coll Antropol; 2015 Sep; 39(3):701-8. PubMed ID: 26898069
[TBL] [Abstract][Full Text] [Related]
19. Long-term administration of galactoside-specific mistletoe lectin in an animal model: no protection against N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder carcinogenesis in rats and no induction of a relevant local cellular immune response.
Kunze E; Schulz H; Adamek M; Gabius HJ
J Cancer Res Clin Oncol; 2000 Mar; 126(3):125-38. PubMed ID: 10741906
[TBL] [Abstract][Full Text] [Related]
20. Interaction of a standardized mistletoe (Viscum album) preparation with antitumor effects of Trastuzumab in vitro.
Weissenstein U; Kunz M; Urech K; Regueiro U; Baumgartner S
BMC Complement Altern Med; 2016 Aug; 16():271. PubMed ID: 27491866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
